Mizuho Securities analyst Salim Syed has maintained their bullish stance on WVE stock, giving a Buy rating yesterday.
Salim Syed’s rating is based on a promising outlook for Wave Life Sciences, driven by several key developments. The company has a clear and established catalyst flow for 2025, which is likely contributing to the recent increase in stock price. The enrollment for the first single-dose cohort of WVE-007 for obesity is complete, with data expected in the second half of 2025, potentially highlighting a unique mechanism for weight loss.
Additionally, Wave Life Sciences has two anticipated data points for AATD in 2025, which could provide insights into dosing regimens. The timeline for WVE-N531’s DMD data remains on track, with no delays expected, and a regulatory update is anticipated soon. Furthermore, the company plans to submit a Ph2/3 IND application for HD in the second half of 2025, adding to the positive momentum.
In another report released yesterday, J.P. Morgan also maintained a Buy rating on the stock with a $21.00 price target.
WVE’s price has also changed dramatically for the past six months – from $5.120 to $11.230, which is a 119.34% increase.